Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder: The first-reported Latin-American case with response to doxycycline.

Autor: Escanilla C; Instituto Chileno de Cabeza y Cuello Santiago Chile., Guavita Falla PM; Departamento de Dermatología Facultad de Medicina Universidad Nacional de Colombia Bogotá Colombia., Cevallos C; Departamento de Dermatología Universidad de Santiago de Chile Santiago Chile., Ávalos Jobet N; Instituto Chileno de Cabeza y Cuello Santiago Chile., Bobadilla Bruneau F; Hospital Barros Luco Trudeau Santiago Chile.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2019 Oct 29; Vol. 7 (12), pp. 2405-2409. Date of Electronic Publication: 2019 Oct 29 (Print Publication: 2019).
DOI: 10.1002/ccr3.2454
Abstrakt: Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder is a provisional entity according to the last WHO-EORTC classification. The treatment of choice has not yet been defined. Local therapies have been used with variable response. Doxycycline as a main treatment option is a potential low-cost and effective alternative for this disorder.
Competing Interests: The authors declared no conflict of interest.
(© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje